Top

Published in:

01-04-2013 | Clinical Trial

Impact of local surgical treatment on survival in young women with T1 breast cancer: long-term results of a population-based cohort

Authors: Ye Won Jeon, Jung Eun Choi, Heung Kyu Park, Ku Sang Kim, Jee Yeon Lee, Young Jin Suh

Published in: Breast Cancer Research and Treatment | Issue 2/2013

Abstract

The aim of this study was to analyze the effect of the type of local surgical treatment on survival in young women aged less than 40 years with T1 breast cancer. We analyzed data from 3,512 patients aged ≤40 years old who were diagnosed with T1 breast cancer from the Korean Breast Cancer Registry database between January 1988 and December 2006 and underwent either breast-conserving therapy (BCT) or mastectomy. The overall survival (OS) and breast-cancer-specific survival (BCSS) were compared between BCT and mastectomy. Of the 3,512 patients analyzed, 1,951 (55.6 %) underwent BCT, and 1,561 (44.4 %) underwent mastectomy. The median follow-up period was 111.0 (79.0–131.5) months. Overall, the 10-year OS rates for BCT and mastectomy were 95 and 92.1 %, respectively (p = 00004), and the 10-year BCSS rates for BCT and mastectomy patients were 96.9 and 94.9 %, respectively (p = 0.12). In node-negative patients, no significant difference was observed in either the OS (adjusted hazard ratio [HR] 1.072; 95 % CI, 0.750–1.5332, p = 0.704) or BCSS (adjusted HR 0.988; 95 % CI, 0.620–1.574, p = 0.960) rate between the BCT and mastectomy groups. In node-positive patients, no significant difference was observed in the OS (adjusted HR 1.634; 95 % CI, 0.982–2.272, p = 0.59) and BCSS (adjusted HR 1.410; 95 % CI, 0.755–2.633, p = 0.281) rates between the BCT and mastectomy groups. In this large, population-based analysis of young women with T1 breast cancer, the OS and BCSS were not different between BCT and mastectomy.

Jung KW, Park S, Kong HJ et al (2012) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat 44:11–24PubMedCrossRef

Horner MJ, Ries LAG, Krapcho M et al (eds) (2009) SEER Cancer Statistics Review 1975-2006, National Cancer Institute, Bethesda. http://seer.cancer.gov/csr/1975_2006. Accessed 14 Jan 2013

Kankerincidentie Nederlandse Kankerregistratie (2010) http://www.iknl.nl/uploaded/docs/Landelijk/cijfers/incidentie%202007/A03_NL.xls. Accessed 14 Jan 2013

Australian Institute of Health and Welfare (AIHW), Australasian Association of Cancer Registries (AACR) (2004) Cancer in Australia 2001, Cancer Series no. 28. Australian Institute of Health and Welfare, Canberra

Han W, Kim SW, Park IA et al (2004) Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer 4:82PubMedCrossRef

Anders CK, Hsu DS, Broadwater G et al (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324–3330PubMedCrossRef

Sarrazin D, Lê M, Rouëssé J et al (1984) Conservative treatment versus mastectomy in breast cancer tumors with macroscopic diameter of 20 millimeters or less: the experience of the Institut Gustave-Roussy. Cancer 53:1209–1213PubMedCrossRef

Fisher B, Anderson S, Redmond CK et al (1995) Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333:1456–1461PubMedCrossRef

Veronesi U, Banfi A, Salvadori B et al (1990) Breast conservation is the treatment of choice in small breast cancer: longterm results of a randomized trial. Eur J Cancer 26:668–670PubMedCrossRef

10.

Veronesi U, Cascinelli N, Mariani L et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1227–1232PubMedCrossRef

11.

Van Dongen JA, Voogd AC, Fentiman IS et al (2000) Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: european organization for research and treatment of cancer 10801 trial. J Natl Cancer Inst 92:1143–1150PubMedCrossRef

12.

Kroman N, Holtveg H, Wohlfahrt J et al (2004) Effect of breast conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 100:688–693PubMedCrossRef

13.

Coulombe G, Tyldesley S, Speers C et al (2007) Is mastectomy superior to breast-conserving treatment for young women? Int J Radiat Oncol Biol Phys 67:1282–1290PubMedCrossRef

14.

Beadle BM, Woodward WA, Tucker SL et al (2009) Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys 73:734–744PubMedCrossRef

15.

van der Sangen MJ, van de Wiel FM, Poortmans PM et al (2011) Are breast conservation and mastectomy equally effective in the treatment of young women with early breast cancer? Long-term results of a population-based cohort of 1,451 patients aged ≤40 years. Breast Cancer Res Treat 127:207–215PubMedCrossRef

16.

Voogd AC, Nielsen M, Peterse JL et al (2001) Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results for two large European randomized trials. J Clin Oncol 19:1688–1697PubMed

17.

De Bock GH, van der Hage JA, Putter H et al (2006) Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European organisation for research and treatment of cancer studies. Eur J Cancer 42:351–356PubMedCrossRef

18.

Monteiro Grillo I, Jorge M, Marques Vidal P et al (2005) The effect of locoregional recurrence on survival and distant metastasis after conservative treatment for invasive breast carcinoma. Clin Oncol 17:111–117CrossRef

19.

Anderson SJ, Wapnir I, Dignam JJ et al (2009) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node negative breast cancer. J Clin Oncol 27:2466–2473PubMedCrossRef

20.

Tanis E, van de Velde CJ, Bartelink H et al (2012) Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10 years in early stage breast cancer. Eur J Cancer 48:1751–1756PubMedCrossRef

21.

Bantema-Joppe EJ, de Munck L, Visser O et al (2011) Early-stage young breast cancer patients: impact of local treatment on survival. Int J Radiat Oncol Biol Phys 81:e553–e559PubMedCrossRef

22.

Edge SB, Byrd DR, Compton CC et al (2009) AJCC cancer staging manual, 7th edn. Springer, New York

23.

Carlson RW, Goldstein LJ, Gradishar WJ et al (1996) NCCN breast cancer practice guidelines. Natl Compr Cancer Netw Oncol 10:47–75

24.

Goldhirsch A, Glick JH, Gelber RD et al (1998) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90:1601–1608PubMedCrossRef

25.

Buchholz TA, WoodwardWA Duan Z et al (2008) Radiation use and long-term survival in breast cancer patients with T1, T2 primary tumors and one to three positive axillary lymph nodes. Int J Radiat Oncol Biol Phys 71:1022–1027PubMedCrossRef

26.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef

27.

Kim JE, Ahn HJ, Ahn JH et al (2012) Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer. J Breast Cancer 15:197–202PubMedCrossRef

28.

Kyndi M, Sørensen FB, Knudsen H et al (2008) Estrogen receptor, progesterone receptor, HER-2, and response to mastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 26:1419–1426PubMedCrossRef

Title: Impact of local surgical treatment on survival in young women with T1 breast cancer: long-term results of a population-based cohort
Authors: Ye Won Jeon
Jung Eun Choi
Heung Kyu Park
Ku Sang Kim
Jee Yeon Lee
Young Jin Suh
Publication date: 01-04-2013
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-013-2456-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Too many statistical errors for meaningful interpretation

Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer

A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer

Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis

Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome

Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer